First Documented Use of Pegcetacoplan for Fibrillary Glomerulonephritis: A Case Report (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0697; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Introduction Guidelines for the management of idiopathic Fibrillary Glomerulonephritis (FGN) with reduced eGFR or nephrotic-range proteinuria are lacking, but B-cell-depleting therapy with Rituximab is currently the preferred therapy...In 2025, losartan and spironolactone were held due to hyponatremia...If treatment results in sustained proteinuria reduction and decreased or resolved C3 deposition on repeat biopsy, this case may provide proof-of-concept support for future studies evaluating C3 blockade in FGN. Updated clinical and histologic outcomes are anticipated by October 2026 for ASN 2026."
Case report • Clinical • Cardiovascular • Chronic Spontaneous Urticaria • Complement-mediated Rare Disorders • Glomerulonephritis • Heart Failure • Hematological Malignancies • Immunology • Lupus Nephritis • Monoclonal Gammopathy • Nephrology • Renal Disease • Urticaria
|
|
Juliano Alhaddad; Yuan Huang; Laura Ferreira Provenzano; Corey J. Cavanaugh
|